Remedium Lifecare Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/11/2025 ,inter alia, to consider and approve Unaudited Standalone and ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Remedium Lifecare Limited has informed BSE that its Board of Directors will meet on Friday, 14th November 2025. The main agenda is to consider and approve the Un-Audited Standalone and Consolidated Financial Results for the second quarter and half year ended 30th September 2025. The company also confirmed that the trading window for insiders and designated persons has been closed since 1st October 2025 and will reopen 48 hours after the results are declared. Note: the filing is signed by Adarsh Munjal, Whole Time Director, and bears company code 539561.
This is a routine regulatory intimation with no new financial information. Investors should watch for the actual Q2/H1 FY26 results on or after 14th November 2025 to assess the company's earnings performance and any directional cue for the stock.